Keyphrases
Percutaneous Coronary Intervention
100%
Drug-eluting Stent
64%
Myocardial Infarction
54%
Randomized Trial
53%
Restenosis
52%
Clopidogrel
46%
Acute Myocardial Infarction
46%
Confidence Interval
44%
Clinical Outcomes
41%
Acute Coronary Syndrome
38%
Hazard Ratio
35%
Stent Thrombosis
33%
ST-elevation Myocardial Infarction (STEMI)
32%
Coronary Artery Disease
30%
Coronary Stenting
29%
Ticagrelor
28%
Patients with Coronary Artery Disease
28%
Stent
28%
Meta-analysis
26%
In-stent Restenosis
25%
Prasugrel
25%
Target Lesion Revascularization
24%
Bleeding
22%
Intracoronary Stenting
22%
Aspirin
22%
Sirolimus-eluting Stent
21%
Abciximab
20%
Prognostic Value
20%
Coronary Stent Placement
20%
Polymorphism
17%
All-cause Mortality
17%
Bare Metal Stent
16%
Angiographic Restenosis
16%
Antithrombotic Therapy
15%
Paclitaxel-eluting Stent
15%
Odds Ratio
14%
Angiography
14%
Pooled Analysis
14%
Drug-eluting Stent Implantation
14%
Sirolimus
13%
Transcatheter Aortic Valve Implantation
13%
Bivalirudin
13%
Randomized Clinical Trial
13%
Revascularization
12%
Dual Antiplatelet Therapy
12%
Primary Percutaneous Coronary Intervention
12%
Myocardial Salvage
12%
Balloon Angioplasty
11%
Optical Coherence Tomography
11%
Adverse Cardiac Events
11%
Medicine and Dentistry
Percutaneous Coronary Intervention
68%
Drug-Eluting Stent
64%
Restenosis
51%
Coronary Artery Disease
40%
Myocardial Infarction
38%
Stenting
34%
Rapamycin
30%
Acute Heart Infarction
28%
Hazard Ratio
26%
Coronary Stenting
25%
Stent Thrombosis
24%
Percutaneous Aortic Valve Replacement
21%
Acute Coronary Syndrome
21%
Target Lesion Revascularization
20%
Meta-Analysis
19%
Paclitaxel
18%
In-Stent Restenosis
18%
Revascularization
17%
Stent Placement
17%
Antiplatelet
17%
Everolimus
17%
Angiography
16%
Bleeding
16%
Percutaneous Transluminal Angioplasty
16%
Stenosis
15%
ST Segment Elevation Myocardial Infarction
13%
Diabetes Mellitus
12%
Optical Coherence Tomography
12%
Clopidogrel
12%
Pooled Analysis
11%
Odds Ratio
11%
Cardiovascular System
10%
Coronary Artery
10%
ST Elevation
9%
Acetylsalicylic Acid
9%
Randomized Clinical Trial
9%
Randomized Controlled Trial
8%
Infarction
8%
Platelet
8%
Antithrombotic
8%
Heart Muscle Revascularization
8%
Ticagrelor
8%
Abciximab
7%
Apoplexy
7%
Major Adverse Cardiac Event
7%
All Cause Mortality
7%
Heart Left Ventricle Ejection Fraction
7%
Zotarolimus
7%
Coronary Artery Bypass Graft
7%
Transluminal Coronary Angioplasty
7%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Infarction
63%
Coronary Artery Disease
53%
Restenosis
46%
Clopidogrel
43%
Acute Heart Infarction
38%
Acute Coronary Syndrome
36%
Rapamycin
35%
Ticagrelor
30%
Bleeding
29%
Antiplatelet
27%
Stent Thrombosis
26%
Prasugrel
23%
ST Segment Elevation Myocardial Infarction
23%
Acetylsalicylic Acid
21%
Abciximab
20%
Paclitaxel
19%
Anticoagulant Agent
16%
Diabetes Mellitus
15%
Infarction
14%
Cerebrovascular Accident
14%
Placebo
14%
Heparin
14%
Bivalirudin
14%
Randomized Controlled Trial
13%
Everolimus
12%
All Cause Mortality
11%
In-Stent Restenosis
11%
Randomized Clinical Trial
9%
Non ST Segment Elevation Myocardial Infarction
9%
Stenosis
9%
Clinical Trial
8%
Monotherapy
7%
C Reactive Protein
7%
Zotarolimus
6%
Adverse Event
6%
Adenosine Diphosphate
6%
Troponin T
6%
Heart Death
6%
Ischemic Heart Disease
5%
Statin (Protein)
5%
Major Adverse Cardiac Event
5%
Fibrinogen Receptor
5%
Stable Angina Pectoris
5%
Cardiovascular Disease
5%
Unstable Angina Pectoris
5%
Thrombosis
5%
Heart Muscle Ischemia
5%
